Jubilant Pharmova Ltd
₹950.90
(2.04%)
Tue, 13 Oct 2026, 07:22 pm
Health Technology
Pharmaceuticals: Major
24.5KJubilant Pharmova Ratios
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 28.49 | 20 | 14.49 | 5.76 | 13.71 | 12.65 | 219.45 | 17.70 | 23.20 | 0 | 16.60 | 21.63 | 20.36 | 18.02 | 4.41 | 12.96 | 14.91 | 0 | 117.13 | 16.90 |
| Price to book ratio | 4.21 | 4.12 | 3.78 | 1.11 | 2.45 | 1.21 | 1.41 | 1.08 | 0.96 | 0.99 | 2.24 | 3.62 | 3.20 | 2.20 | 0.71 | 2.28 | 1.16 | 0.82 | 1.66 | 2.26 |
| Price to sales ratio | 2.52 | 2.52 | 2.33 | 0.46 | 1.53 | 0.85 | 0.75 | 0.53 | 0.44 | 0.42 | 1.14 | 2.15 | 1.76 | 1.15 | 0.66 | 1.78 | 1.01 | 0.71 | 1.35 | 1.96 |
| Price to cash flow ratio | 243.70 | 23.59 | 22.34 | 3.52 | 10.26 | 10.37 | 6.18 | 3.62 | 5.35 | 5.34 | 8.66 | 11.94 | 11.96 | 11.32 | 3.19 | 7.24 | 8.74 | 10.18 | 11.99 | 16.21 |
| Enterprise value | 4314Cr | 5359Cr | 7409Cr | 5160Cr | 8486Cr | 5826Cr | 6802Cr | 6251Cr | 6605Cr | 6827Cr | 10615Cr | 15991Cr | 16256Cr | 13823Cr | 7372Cr | 12995Cr | 8378Cr | 7096Cr | 11725Cr | 15808Cr |
| Enterprise value to EBITDA ratio | 19.94 | 20.47 | 16.01 | 7.65 | 12.75 | 10.61 | 8.14 | 5.98 | 7.02 | 10.46 | 8.40 | 12.37 | 11.18 | 8.09 | 4.64 | 8.91 | 6.94 | 9.33 | 13.08 | 15.17 |
| Debt to equity ratio | 0.88 | 1.82 | 1.68 | 3.06 | 1.45 | 1.81 | 1.69 | 1.52 | 1.67 | 1.95 | 1.51 | 1.18 | 0.85 | 1.01 | 0.86 | 0.60 | 0.60 | 0.68 | 0.67 | 0.44 |
| Return on equity % | 19.50 | 26.33 | 37.04 | 22.44 | 24.38 | 10.53 | 0.66 | 6.43 | 4.26 | -2.27 | 14.46 | 17.98 | 17.09 | 12.92 | 13.02 | 11.10 | 8.23 | -1.14 | 1.42 | 14.36 |
Jubilant Pharmova Ltd Ratios
The Jubilant Pharmova Ltd Ratios page provides a complete fundamental analysis of Jubilant Pharmova Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Jubilant Pharmova Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Jubilant Pharmova Ltd (NSE: JUBLPHARMA, BSE: 530019) is currently trading at ₹950.90, with a market capitalization of ₹14832.26Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Jubilant Pharmova Ltd remains a key stock for fundamental analysis using Jubilant Pharmova Ltd Ratios.
Jubilant Pharmova Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Jubilant Pharmova Ltd P/E ratio currently stands at 16.90, making it one of the most tracked metrics in Jubilant Pharmova Ltd Ratios.
Historically, the Jubilant Pharmova Ltd P/E ratio has shown strong fluctuations:
- 2024: 16.90
- 2023: 117.13
- 2022: 0
- 2021: 14.91
- 2020: 12.96
The decline in Jubilant Pharmova Ltd P/E ratio suggests improving earnings relative to stock price.
Price to Book Ratio (P/B)
The Jubilant Pharmova Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 2.26.
Historical P/B trend:
- 2024: 2.26
- 2023: 1.66
- 2022: 0.82
- 2021: 1.16
Jubilant Pharmova Ltd shows reasonable valuation compared to its asset base.
Price to Sales Ratio (P/S)
The Jubilant Pharmova Ltd P/S ratio currently stands at 1.96, an important part of Jubilant Pharmova Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 1.96
- 2023: 1.35
- 2022: 0.71
- 2021: 1.01
The rising Jubilant Pharmova Ltd P/S ratio indicates improved revenue valuation by investors.
Jubilant Pharmova Ltd Price to Cash Flow Ratio (P/CF)
The Jubilant Pharmova Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 16.21.
Historical Jubilant Pharmova Ltd Price to Cash Flow Ratio:
- 2024: 16.21
- 2023: 11.99
- 2022: 10.18
- 2021: 8.74
- 2020: 7.24
The rising Jubilant Pharmova Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.
Jubilant Pharmova Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Jubilant Pharmova Ltd EV currently stands at ₹15808Cr, representing the total company valuation including debt.
Historical EV trend:
- 2024: 15808Cr
- 2023: 11725Cr
- 2022: 7096Cr
- 2021: 8378Cr
Jubilant Pharmova Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.
EV/EBITDA Ratio
The Jubilant Pharmova Ltd EV/EBITDA ratio is currently 15.17, a key metric in Jubilant Pharmova Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 15.17
- 2023: 13.08
- 2022: 9.33
- 2021: 6.94
Higher Jubilant Pharmova Ltd EV/EBITDA suggests premium valuation.
Jubilant Pharmova Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Jubilant Pharmova Ltd D/E ratio is currently 0.44, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0.44
- 2023: 0.67
- 2022: 0.68
- 2021: 0.60
Jubilant Pharmova Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Jubilant Pharmova Ltd ROE currently stands at 14.36%, showing profitability and capital efficiency.
Historical ROE:
- 2024: 14.36
- 2023: 1.42
- 2022: -1.14
- 2021: 8.23
Jubilant Pharmova Ltd maintains stable profitability levels.
Jubilant Pharmova Ltd Ratios Analysis Summary
The Jubilant Pharmova Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Jubilant Pharmova Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Jubilant Pharmova Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.
